April Zambelli-Weiner
April Zambelli-Weiner has a total of 33 co-authors. Here are the top co-authors by number of shared publications:
Carter A Little
TTi Health Research & Economics, Westminster, MD, USA
2 shared publications- Dipak Delvadia
Drexel University College of Medicine, Philadelphia, PA, USA
2 shared publications - Elizabeth Brooks
TTi Health Research & Economics, Westminster, MD, USA
2 shared publications Matt W Yuen
TTi Health Research & Economics, Westminster, MD, USA
2 shared publicationsRobert L Bauserman
TTi Health Research & Economics, Westminster, MD, USA
2 shared publications- Alexander A. Khalessi
Department of Neurosurgery, University of California, San Diego, La Jolla, CA, USA
1 shared publication
Latest Publications
- 3 November 2026
- Published by Wolters Kluwer Health in Neurosurgery
Two Decades of Neurosurgical Device Innovation: A Comprehensive Analysis of FDA Authorization Trends From 7800 Approvals by Subspecialty, Regulatory Pathway, and Approval Time
BACKGROUND AND OBJECTIVES: Technological progress has accelerated neurosurgical care, yet a panoramic view of these innovations remains lacking. This study aims to analyze all US Food and Drug Administration (FDA) authorizations issued from 2000 to 2023 to map neurosurgical device output by subspecialty, compare regulatory pathways and approval times, and identify factors affecting market entry. METHODS: All devices cleared or approved by the FDA Neurology and Orthopedic Review Panels (January 2000-December 2023) were extracted from publicly available 510(k), De Novo, Humanitarian Device Exemption, and Premarket Approval databases. Devices were assigned to 1 of 9 neurosurgical subspecialties and stratified by regulatory pathway, device class, company maturity, and geographic origin. Descriptive statistics, analysis of variance, and Welch t -tests assessed temporal and categorical differences. RESULTS: Of 16 064 devices reviewed by the FDA Neurology and Orthopedic panels, 7873 (49.0%) were neurosurgical, rising 172.1% over the period. Spine and peripheral nerve (5227 devices) and stereotactic and functional (1378) dominated volume and number of new market entries, while cerebrospinal fluid disorders (n = 149) and cranial trauma (n = 111) had fewer approvals. Cerebrovascular and endovascular (95.5%) and cranial trauma (200.0%) showed the largest growth rates, while cerebrospinal fluid disorders (−54.2%) and general cranial surgery (−34.5%) declined over time. Mean approval time varied by subspecialty ( P < .001), the shortest for spine and peripheral nerve (119.0 ± 102.7 days) and the longest for stereotactic and functional (158.7 ± 121.5 days). Approval or clearance times were strongly influenced by regulatory pathway and device class (both P < .001), with Premarket Approval devices (584.8 ± 323.3 days) the longest. Mature companies achieved faster approvals compared with startups (114.9 ± 97.0 vs 174.5 ± 133.9 days, P < .001). CONCLUSION: Neurosurgical device output has more than doubled, but volume concentrates where predicates are rich and reimbursement established, not where clinical need or novelty is the greatest. Pathway architecture, device complexity, and sponsor experience influence approval efficiency more than novelty.
- 3 November 2026
- Published by Wolters Kluwer Health in Neurosurgery
Two Decades of Neurosurgical Device Innovation: A Comprehensive Analysis of FDA Authorization Trends From 7800 Approvals by Subspecialty, Regulatory Pathway, and Approval Time
BACKGROUND AND OBJECTIVES: Technological progress has accelerated neurosurgical care, yet a panoramic view of these innovations remains lacking. This study aims to analyze all US Food and Drug Administration (FDA) authorizations issued from 2000 to 2023 to map neurosurgical device output by subspecialty, compare regulatory pathways and approval times, and identify factors affecting market entry. METHODS: All devices cleared or approved by the FDA Neurology and Orthopedic Review Panels (January 2000-December 2023) were extracted from publicly available 510(k), De Novo, Humanitarian Device Exemption, and Premarket Approval databases. Devices were assigned to 1 of 9 neurosurgical subspecialties and stratified by regulatory pathway, device class, company maturity, and geographic origin. Descriptive statistics, analysis of variance, and Welch t -tests assessed temporal and categorical differences. RESULTS: Of 16 064 devices reviewed by the FDA Neurology and Orthopedic panels, 7873 (49.0%) were neurosurgical, rising 172.1% over the period. Spine and peripheral nerve (5227 devices) and stereotactic and functional (1378) dominated volume and number of new market entries, while cerebrospinal fluid disorders (n = 149) and cranial trauma (n = 111) had fewer approvals. Cerebrovascular and endovascular (95.5%) and cranial trauma (200.0%) showed the largest growth rates, while cerebrospinal fluid disorders (−54.2%) and general cranial surgery (−34.5%) declined over time. Mean approval time varied by subspecialty ( P < .001), the shortest for spine and peripheral nerve (119.0 ± 102.7 days) and the longest for stereotactic and functional (158.7 ± 121.5 days). Approval or clearance times were strongly influenced by regulatory pathway and device class (both P < .001), with Premarket Approval devices (584.8 ± 323.3 days) the longest. Mature companies achieved faster approvals compared with startups (114.9 ± 97.0 vs 174.5 ± 133.9 days, P < .001). CONCLUSION: Neurosurgical device output has more than doubled, but volume concentrates where predicates are rich and reimbursement established, not where clinical need or novelty is the greatest. Pathway architecture, device complexity, and sponsor experience influence approval efficiency more than novelty.
- Open Access
- 5 October 2026
- Published by Springer Nature in PharmacoEconomics - Open
- Vol. 10 (6) , 1117-1133
Budget Impact Model of a Novel cfRNA Test-and-Treat Strategy for Preeclampsia in Advanced Maternal Age Pregnancies Compared with Current Guidelines
- 5 October 2026
- Published by Springer Nature in PharmacoEconomics - Open
- Vol. 10 (6) , 1117-1133
Open AccessBudget Impact Model of a Novel cfRNA Test-and-Treat Strategy for Preeclampsia in Advanced Maternal Age Pregnancies Compared with Current Guidelines
- Open Access
- 14 April 2025
- Published by Elsevier in International Journal of Pediatric Otorhinolaryngology
- Vol. 193, 112356
Clinical utility of an optical coherence tomography middle ear scope: Interim results of the modification of antibiotic treatment intervention in children (OTO-MATIC) pragmatic cluster randomized controlled trial (RCT)
- 14 April 2025
- Published by Elsevier in International Journal of Pediatric Otorhinolaryngology
- Vol. 193, 112356
Open AccessClinical utility of an optical coherence tomography middle ear scope: Interim results of the modification of antibiotic treatment intervention in children (OTO-MATIC) pragmatic cluster randomized controlled trial (RCT)
- Open Access
- 1 January 2020
- Published by Taylor & Francis in ClinicoEconomics and Outcomes Research
- Vol. 12, 299-306
The CHOICES Study: Facility Level Comparative Cost, Resource Utilization, and Outcomes Analysis of Myomectomy Compared to Transcervical Fibroid Ablation
Purpose: The CHOICES study compared short-term resource utilization, facility costs, and perioperative patient outcomes between transcervical fibroid ablation (TFA) with the Sonata (R) system and myomectomy through a case-matched comparative trial design. This is the first facility-level comparative study conducted for TFA. Patients and Methods: The study enrolled 88 patients from 4 centers equally divided among the two cohorts. The TFA arm consisted of 44 women who had enrolled in the SONATA Pivotal IDE trial, whereas the myomectomy arm included 44 patients who were identified through retrospective case-matching to the enrolled SONATA patients at the same 4 centers. Results: TFA had a significantly lower mean operating room duration (90 minutes) and length of stay (5.2 hours) than myomectomy (143 minutes and 45.8 hours, respectively). The average total mean facility costs for TFA procedure ($7,563) were significantly lower than those associated with myomectomy ($11,425; p=0.002). TFA mean facility costs were also compared with other stratifications of myomectomy (inpatient or outpatient and surgical route). TFA facility costs were significantly lower than that associated with inpatient, abdominal, or laparoscopic myomectomy (all p<0.001). Conclusion: TFA using the Sonata system has a significantly shorter operating room time and length of stay than myomectomy for the treatment of symptomatic uterine fibroids. All procedure, anesthesia, laboratory, pathology, and pharmacy costs were significantly higher for myomectomy as compared to TFA. TFA was also associated with significantly lower facility procedure-related costs compared to myomectomy, including inpatient, abdominal, or laparoscopic myomectomy.
- 1 January 2020
- Published by Taylor & Francis in ClinicoEconomics and Outcomes Research
- Vol. 12, 299-306
Open AccessThe CHOICES Study: Facility Level Comparative Cost, Resource Utilization, and Outcomes Analysis of Myomectomy Compared to Transcervical Fibroid Ablation
Purpose: The CHOICES study compared short-term resource utilization, facility costs, and perioperative patient outcomes between transcervical fibroid ablation (TFA) with the Sonata (R) system and myomectomy through a case-matched comparative trial design. This is the first facility-level comparative study conducted for TFA. Patients and Methods: The study enrolled 88 patients from 4 centers equally divided among the two cohorts. The TFA arm consisted of 44 women who had enrolled in the SONATA Pivotal IDE trial, whereas the myomectomy arm included 44 patients who were identified through retrospective case-matching to the enrolled SONATA patients at the same 4 centers. Results: TFA had a significantly lower mean operating room duration (90 minutes) and length of stay (5.2 hours) than myomectomy (143 minutes and 45.8 hours, respectively). The average total mean facility costs for TFA procedure ($7,563) were significantly lower than those associated with myomectomy ($11,425; p=0.002). TFA mean facility costs were also compared with other stratifications of myomectomy (inpatient or outpatient and surgical route). TFA facility costs were significantly lower than that associated with inpatient, abdominal, or laparoscopic myomectomy (all p<0.001). Conclusion: TFA using the Sonata system has a significantly shorter operating room time and length of stay than myomectomy for the treatment of symptomatic uterine fibroids. All procedure, anesthesia, laboratory, pathology, and pharmacy costs were significantly higher for myomectomy as compared to TFA. TFA was also associated with significantly lower facility procedure-related costs compared to myomectomy, including inpatient, abdominal, or laparoscopic myomectomy.
- Open Access
- 1 January 2020
- Published by Taylor & Francis in ClinicoEconomics and Outcomes Research
- Vol. ume 12, 1-11
The INSPIRE Comparative Cost Study: 12-Month Health Economic and Clinical Outcomes Associated with Hysterectomy, Myomectomy, and Treatment with the Sonata System
Purpose: The INSPIRE study compared perioperative and 12-month health economic and clinical outcomes associated with hysterectomy, myomectomy, and sonography-guided transcervical fibroid ablation (TFA) using the Sonata® system. Patients and Methods: Cost and health care resource utilization (HCRU) data for TFA were obtained from a prospective, multicenter, single-arm clinical trial. Data for hysterectomy and myomectomy arms were derived from the Truven Health MarketScan commercial payer claims database. The Truven data was used to determine health economic outcomes and costs for the hysterectomy and myomectomy arms. For each arm, payer perspective costs were estimated from the available charge and HCRU data. Results: TFA with Sonata had significantly lower mean length of stay (LOS) of 5 hrs versus hysterectomy (73 hrs) or myomectomy (79 hrs; all p< 0.001). The average payer cost for TFA treatment, including the associated postoperative HCRU was $8,941. This was significantly lower compared to hysterectomy ($24,156) and myomectomy ($22,784; all p< 0.001). In the TFA arm, there were no device- or procedure-related costs associated with complications during the peri- or postoperative time frame. TFA subjects had significantly lower costs associated with complications, prescription medications, and radiology. Conclusion: Compared to hysterectomy and myomectomy, TFA treatment with the Sonata system was associated with significantly lower index procedure cost, complication cost, and LOS, contributing to a lower total payer cost through 12 months.
- 1 January 2020
- Published by Taylor & Francis in ClinicoEconomics and Outcomes Research
- Vol. ume 12, 1-11
Open AccessThe INSPIRE Comparative Cost Study: 12-Month Health Economic and Clinical Outcomes Associated with Hysterectomy, Myomectomy, and Treatment with the Sonata System
Purpose: The INSPIRE study compared perioperative and 12-month health economic and clinical outcomes associated with hysterectomy, myomectomy, and sonography-guided transcervical fibroid ablation (TFA) using the Sonata® system. Patients and Methods: Cost and health care resource utilization (HCRU) data for TFA were obtained from a prospective, multicenter, single-arm clinical trial. Data for hysterectomy and myomectomy arms were derived from the Truven Health MarketScan commercial payer claims database. The Truven data was used to determine health economic outcomes and costs for the hysterectomy and myomectomy arms. For each arm, payer perspective costs were estimated from the available charge and HCRU data. Results: TFA with Sonata had significantly lower mean length of stay (LOS) of 5 hrs versus hysterectomy (73 hrs) or myomectomy (79 hrs; all p< 0.001). The average payer cost for TFA treatment, including the associated postoperative HCRU was $8,941. This was significantly lower compared to hysterectomy ($24,156) and myomectomy ($22,784; all p< 0.001). In the TFA arm, there were no device- or procedure-related costs associated with complications during the peri- or postoperative time frame. TFA subjects had significantly lower costs associated with complications, prescription medications, and radiology. Conclusion: Compared to hysterectomy and myomectomy, TFA treatment with the Sonata system was associated with significantly lower index procedure cost, complication cost, and LOS, contributing to a lower total payer cost through 12 months.
- Open Access
- 1 November 2006
- Published by Oxford University Press (OUP) in Journal of AOAC INTERNATIONAL
- Vol. 89 (6) , 1617-1621
Quantitative Assessment of Hard Surface Disinfectant Activity Against the Foodborne Pathogen Listeria monocytogenes
Listeria monocytogenes is an important foodborne pathogen that must be controlled to ensure food safety. For the years 2003 and 2004, L. monocytogenes caused 20 deaths per 100 listeriosis cases and was responsible for most food recalls for pathogen contamination. The objective of this work was to develop a quantitative method to assess disinfectant activity against L. monocytogenes. Standard procedures for testing disinfectants against 3 bacteria are described in the AOAC Official Methods of Analysis as use-dilution methods. No standard methods are provided for L. monocytogenes. In this study, preliminary efficacy of a quaternary ammonium compound with hydroperoxide ion was determined for 25 bacterial strains. The zones of inhibition ranged from 7.0 to 12.5 mm, and the minimum inhibitory concentration ranged from 5 to 250 ppm. For final efficacy, stainless steel carriers were contaminated with L. monocytogenes and tested separately for 5, 10, and 15 min in disinfectant or phenol. After exposure, the carriers were placed into 2 series of D/E neutralization broth. For 3 replications with duplicate samples, the phenol coefficient was 3.3. This research presents a technique-sensitive method that provides quantitative data for comparison and analysis of disinfectant activity against L. monocytogenes.
- 1 November 2006
- Published by Oxford University Press (OUP) in Journal of AOAC INTERNATIONAL
- Vol. 89 (6) , 1617-1621
Open AccessQuantitative Assessment of Hard Surface Disinfectant Activity Against the Foodborne Pathogen Listeria monocytogenes
Listeria monocytogenes is an important foodborne pathogen that must be controlled to ensure food safety. For the years 2003 and 2004, L. monocytogenes caused 20 deaths per 100 listeriosis cases and was responsible for most food recalls for pathogen contamination. The objective of this work was to develop a quantitative method to assess disinfectant activity against L. monocytogenes. Standard procedures for testing disinfectants against 3 bacteria are described in the AOAC Official Methods of Analysis as use-dilution methods. No standard methods are provided for L. monocytogenes. In this study, preliminary efficacy of a quaternary ammonium compound with hydroperoxide ion was determined for 25 bacterial strains. The zones of inhibition ranged from 7.0 to 12.5 mm, and the minimum inhibitory concentration ranged from 5 to 250 ppm. For final efficacy, stainless steel carriers were contaminated with L. monocytogenes and tested separately for 5, 10, and 15 min in disinfectant or phenol. After exposure, the carriers were placed into 2 series of D/E neutralization broth. For 3 replications with duplicate samples, the phenol coefficient was 3.3. This research presents a technique-sensitive method that provides quantitative data for comparison and analysis of disinfectant activity against L. monocytogenes.